Abstract:Objective To study the relationship between the chemokine CX3CL1/ CX3CR1 and platinum drug resistance, as well as prognosis in ovarian cancer patients. To dynamically detect the resistance nude mice model of CX3CL1 and its receptor CX3CR1 in the course of platinum resistance. To analyze the expression of CX3CL1, CX3CR1 and the correlation of Fas signaling pathway. Methods The cancer gene atlas(TCGA) database of patients with ovarian cancer genome-wide expression was employed to analyze the relation-ship of CX3CL1/ CX3CR1 in platinum sensitivity or resistant patients with clinical features. Ovarian cancer SKOV3 sensitive cells(SK-OV3-GFP) with green fluorescent marker and cisplatin resistant cells(SKOV3-GFP / DDPⅢ) were subcutaneously injected in nude mice. After xenograft was constracted, cisplatin was intraperitoneally injected. Real time fluorescence quantitative-PCR(qRT-PCR) was used to detect the expression of CX3CL1, CX3CR1 and genes on Fas signal pathway after 0, 2, 5, 8 times of cisplatin injection. Results CX3CL1 expression was negatively correlated with FIGO and platinum resistance(r=-0. 112,P= 0. 030;r=-0. 106,P= 0. 044), CX3CR1 expression was negatively correlated with progression-free survival time(r = -0. 130,P = 0. 029) and positively correlated with 1-year re-lapse rate(r= 0. 119,P = 0. 045). The average expression of CX3CL1 in platinum sensitive group was 3. 96±0. 039, higher than 3. 64± 0. 55 of platinum resistant group(P= 0. 000). After the intervention of cisplatin, xenograft grew gradually. The weight of xenograft in SK-OV3-GFP / DDPⅢ group was higher than SKOV3-GFP group, and xenograft in the both two groups shrank at the fifth time of infection. After cisplatin stimulation, the expression of CX3CL1/ CX3CR1 in SKOV3-GFP group increased significantly(P= 0. 001, P= 0. 002), but it remained low in SKOV3-GFP / DDPⅢ group. The expression of Fas and FADD of Fas signal pathway in SKOV3 GFP / DDPⅢ group was also significantly lower than them in SKOV3-GFP group(P<0. 001). However, PARP1 gene significantly rose in SKOV3GFP / DDPⅢgroup than that in SKOV3-GFP group(P<0. 001). The expression of CX3CL1 and CX3CR1 was positively correlated with Fas and FADD, while it was negatively correlated with PARP1 of Fas signaling pathways. Conclusion The down-regulation of CX3CL1 and CX3CR1 is associated with platinum resistance. They may play a role in maintain the sensitivity of tumor cells to platinum. The low expression of CX3CL1 and CX3CR1 may suppress Fas signal pathway through some mechanism, resulting in transduction disorder, inhibiting cell apop-tosis and inducing platinum resistance of ovarian cancer. The lower expression of drug-resistant cells may be a mechanism inhibiting Fas signaling pathways, which make its conduction misbalance, finally inhibiting cell apoptosis, inducing the resistance of ovarian cancer. It may be a platinum promote ovarian cancer therapy targeting molecules.

NKX2-8 Deletion-Induced Reprogramming of Fatty Acid Metabolism Confers Chemoresistance in Epithelial Ovarian Cancer.

NKX2-8 Deletion Confers Chemoresistance via Reprogramming of Fatty Acid Metabolism in Epithelial Ovarian Cancer

FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer

Nuclear Orphan Receptor NR2F6 Confers Cisplatin Resistance in Epithelial Ovarian Cancer Cells by Activating the Notch3 Signaling Pathway.

Chemokine CXCL-2 Regulates Resistance to Platinum in Epithelial Ovarian Cancer by Mediating ATR/CHK1 Signaling Pathway

NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance

Inhibition of Fatty Acid Catabolism Augments the Efficacy of Oxaliplatin-Based Chemotherapy in Gastrointestinal Cancers.

Knockdown of FUSE Binding Protein 1 Enhances the Sensitivity of Epithelial Ovarian Cancer Cells to Carboplatin

Chemokine CX3CL1/CX3CR1 biological axis promote ovarian cancer cell apotosis induced by platinum drug

Targeting RNF8 Effectively Reverses Cisplatin and Doxorubicin Resistance in Endometrial Cancer.

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer

Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence

SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells

Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2

The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells

FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

Data from Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer

Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance

FXN targeting induces cell death in ovarian cancer stem-like cells through PRDX3-Mediated oxidative stress